ESR1 and neoplasm: In addition to the mutated peptides, we also included their respective wild-type peptides to serve both as a negative control and a potential immunotherapeutic target, as ESR1 is a highly enriched tumor-associated antigen (TAA) in ER+ breast tumors (Supplementary Fig. S2).